COPD Landmark Trial UPLIFT® Proves Tiotropium Sustains Lung Function Improvements Over Four Years And Improves Survival Rate
Results of the UPLIFT® trial, presented at the European Respiratory Society (ERS) Annual Congress, demonstrated that tiotropium (Spiriva®) administered to Chronic Obstructive Pulmonary Disease (COPD) patients, showed sustained improvements in lung function for up to 4 years (p
More: continued here
Filed under: Pharma Industry on October 13th, 2008